The global pruritus therapeutics market was valued at $7,849.4 million in 2021, and is projected to reach $11,186.15 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.
Pruritus therapeutics are medications used in treatment of pruritus. Pruritus causes itching of skin, owing to number of issues such as dry skin, allergy, and other ailments. It is a skin ailment that, if ignored, can cause persistent pain and have a negative influence on quality of life. For instance, anxiety, attention-deficit, or hyperactivity disorder and sleep disturbance can all be brought on by pruritus. In addition, it might result in systemic and mental conditions, if left untreated. A more significant underlying cause is typically indicated when pruritus persists for a longer time. A heightened inflammatory response to a multitude of possible irritants, such as dust, environmental pollutants, animals, and certain food can cause eczema, also known as atopic dermatitis. Atopic dermatitis commonly manifests as rashes, scaly areas, and itching on face, arms, or legs. Allergic contact dermatitis happens when people come into touch with substances that might harm their skin, such as chemicals. Typical products that cause contact dermatitis include watches, soaps, garments, and jewelry produced with potentially irritating substances.
Medical professionals have utilized corticosteroids as a topical dosage form for treating pruritus for many years. The first-line pharmacological therapy for pruritus and associated skin itch diseases such AD, allergic contact dermatitis, and lichen planus is corticosteroids. Pruritus, a common sign of autoimmune and inflammatory skin conditions, can be extremely uncomfortable and negatively affect a patient's quality of life. Moisturizers, emollients, and barrier repair creams usually lessen pruritus by enhancing barrier function.
Leading market players are significantly investing in research and development to create innovative pruritus therapies. Investments are also being made to advance existing therapeutics. In addition, launching new medications and building a strong product pipeline is the major focus of key players. Moreover, owing to their low cost and convenience of availability, over-the-counter topical medicines are in high demand. As a result, patients are turning more frequently to over-the-counter treatments. These drivers provide a favorable environment for increasing sales of pruritus products and for growth of the overall market. However, lack of knowledge regarding cause of the disease creates hindrance to the market. Moreover, patent expiry of various pruritus therapeutic products provide a greater opportunity for market players to grow their business.
The pruritus therapeutics market is segmented on the basis of drug type, disease, distribution channel, and region. On the basis of drug type, the market is segmented into corticosteroids, antihistamines, local anesthetics, immunosuppressants, and others. On the basis of disease type, it is segmented into atopic dermatitis, allergic contact dermatitis, urticaria, and others. On the basis of distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment is further segmented on the basis of route of administration into oral route, parenteral route, and topical route. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Major companies profiled in this report include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Cara therapeutics, Inc., Cipla Ltd., Eilly Lilly and Company, Evelo Bioscience, Galderma S.A., LEO Pharma, MC2 Therapeuitics, Novan Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Trevi therapeutics and Viatris Inc.
Pruritus therapeutics are medications used in treatment of pruritus. Pruritus causes itching of skin, owing to number of issues such as dry skin, allergy, and other ailments. It is a skin ailment that, if ignored, can cause persistent pain and have a negative influence on quality of life. For instance, anxiety, attention-deficit, or hyperactivity disorder and sleep disturbance can all be brought on by pruritus. In addition, it might result in systemic and mental conditions, if left untreated. A more significant underlying cause is typically indicated when pruritus persists for a longer time. A heightened inflammatory response to a multitude of possible irritants, such as dust, environmental pollutants, animals, and certain food can cause eczema, also known as atopic dermatitis. Atopic dermatitis commonly manifests as rashes, scaly areas, and itching on face, arms, or legs. Allergic contact dermatitis happens when people come into touch with substances that might harm their skin, such as chemicals. Typical products that cause contact dermatitis include watches, soaps, garments, and jewelry produced with potentially irritating substances.
Medical professionals have utilized corticosteroids as a topical dosage form for treating pruritus for many years. The first-line pharmacological therapy for pruritus and associated skin itch diseases such AD, allergic contact dermatitis, and lichen planus is corticosteroids. Pruritus, a common sign of autoimmune and inflammatory skin conditions, can be extremely uncomfortable and negatively affect a patient's quality of life. Moisturizers, emollients, and barrier repair creams usually lessen pruritus by enhancing barrier function.
Leading market players are significantly investing in research and development to create innovative pruritus therapies. Investments are also being made to advance existing therapeutics. In addition, launching new medications and building a strong product pipeline is the major focus of key players. Moreover, owing to their low cost and convenience of availability, over-the-counter topical medicines are in high demand. As a result, patients are turning more frequently to over-the-counter treatments. These drivers provide a favorable environment for increasing sales of pruritus products and for growth of the overall market. However, lack of knowledge regarding cause of the disease creates hindrance to the market. Moreover, patent expiry of various pruritus therapeutic products provide a greater opportunity for market players to grow their business.
The pruritus therapeutics market is segmented on the basis of drug type, disease, distribution channel, and region. On the basis of drug type, the market is segmented into corticosteroids, antihistamines, local anesthetics, immunosuppressants, and others. On the basis of disease type, it is segmented into atopic dermatitis, allergic contact dermatitis, urticaria, and others. On the basis of distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment is further segmented on the basis of route of administration into oral route, parenteral route, and topical route. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Major companies profiled in this report include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Cara therapeutics, Inc., Cipla Ltd., Eilly Lilly and Company, Evelo Bioscience, Galderma S.A., LEO Pharma, MC2 Therapeuitics, Novan Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Trevi therapeutics and Viatris Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pruritus therapeutics market analysis from 2021 to 2031 to identify the prevailing pruritus therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the pruritus therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global pruritus therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug type
- Corticosteroids
- Antihistamines
- Local Anesthetics
- Immunosuppressant
- Others
By Disease Type
- Atopic Dermatitis
- Allergic Contact Dermatitis
- Urticaria
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug stores Retail Pharmacies
- Route of Administration
- Oral
- Parenteral
- Topical
- Online providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- UK
- Italy
- Spain
- Rest of Europe
- Germany
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- AbbVie Inc.
- Amgen Inc.
- Bausch Health Companies Inc.
- Cara therapeutics, Inc.
- Cipla Ltd.
- Eilly Lilly and company
- Evelo Biosciences
- Galderma S.A.
- LEO Pharma
- MC2 therapeuitics
- Novan, Inc
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc
- Sanofi
- Trevi therapeutics
- Viatris Inc. (Mylan NV)
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE
CHAPTER 5: PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE
CHAPTER 6: PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: PRURITUS THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Pruritus Therapeutics Market," the pruritus therapeutics market was valued at $7.9 billion in 2021, and is estimated to reach $11.2 billion by 2031, growing at a CAGR of 3.6% from 2022 to 2031.The most prevalent sign of skin disease, pruritus (itching), is best described as a sensation that makes people want to scratch. It may also be the primary symptom of psychiatric and systemic illnesses. When an underlying cause cannot be diagnosed, managing pruritus can be challenging. Creation of efficient treatment solutions for pruritus has proven to be particularly challenging, owing to poorly known pathogenesis. So far, there is no treatment for pruritus that is accepted everywhere. Instead, a customized strategy to pruritus control is used. However, recent developments in diagnosis of pathophysiology of pruritus have shown opportunities to explore causes of this disease and provided opportunities for further developments of therapeutics.
High demand for over-the-counter topical treatments, new product releases, and a solid pipeline are the pruritus therapeutics market trends. However, an insufficient knowledge about the underlying causes of pruritus is a restraint that prevents the pruritus therapeutics market growth. Moreover, patent expiration of several pruritus treatments is the prospect that may provide a favorable environment for the market expansion.
Despite conventional pharmacotherapies having well-established antipruritic characteristics, these treatments frequently fall short of providing enough relief for affected individuals. As a result of expanding pruritic research field, additional experimental and clinical data have emerged, consistently enhancing the possibility for introducing new approaches to treatment.
New therapeutic modalities have been created and are expected to soon be added to the group of antipruritic medications that dermatologists employ on a daily basis.
The global market for pruritus therapies is segmented on the basis of drug type, disease, distribution channel and region. On the basis of drug type, the pruritus therapeutics market size is segmented into corticosteroids, antihistamines, local anesthetics, immunosuppressants, and others. The corticosteroids segment generated highest revenue in 2021, owing to high prevalence rate throughout the world and resulting high demand for corticosteroids as treatment to cure pruritus. The corticosteroid segment was the largest segment in 2021, and is expected to grow at a CAGR of 4.4% during the forecast period. Furthermore, the others segment is expected to grow at a CAGR of 4.0% during the forecast period.
A more significant underlying cause is typically indicated when pruritus persists for a longer time. On the basis of disease type, the global pruritus therapeutics market is divided into atopic dermatitis, allergic contact dermatitis, urticaria, and others. The atopic dermatitis segment is expected to grow at a CAGR of 3.2% during the forecast period. A heightened inflammatory response to a variety of potential irritants, such as dust, environmental pollutants, animals, certain foods, can cause eczema, which is also known as atopic dermatitis. The causes and prevalence of large number of the factors that lead to generation of the disease propels growth of the segment.
By distribution channels, the pruritus therapeutics market share market is divided into hospital pharmacies, drug store & retail pharmacies, and online providers. The drug stores & retail pharmacies segment is further divided, on basis of route of administration, into oral route, parenteral route, and topical route.
This segment held the largest share of the market, owing to easy accessibility, high availability, and cost-effectiveness of services they provide. However, the online providers segment is expected to grow, owing to digitalization and convenient services at a CAGR of 5.5% during the forecast period.
Region wise, North America acquired a major share of the market in the year 2021, owing to presence of key players, rise in government initiatives, well-developed healthcare infrastructure, and increase in prevalence of skin related health issues. However, Asia-Pacific is expected to witness highest growth during the forecast period. Increase in R&D investments, growth in awareness of newer therapies, and rise in consumer preferences toward OTC products are prime factors that supplement growth of the Asia-Pacific market. However, insufficient knowledge about pathogenesis and treatment hinders the pruritus therapeutics industry.
Key Findings of the Study
- On the basis of drug type, the corticosteroids segment held the largest market share in 2021, and is expected to remain dominant during the forecast period.
- On the basis of disease type, the atopic dermatitis segment held the largest market share in 2021, and the others segment is expected to be the fastest growing segment during the forecast period.
- On the basis of distribution channel, the drug store and retail pharmacies segment held largest market share in 2021, whereas the online providers segment is expected to be the fastest growing segment during the forecast period.
- Region wise, North America held the largest market segment in 2021, and Asia-Pacific is expected to experience growth at the highest rate during the forecast period.
Companies Mentioned
- Abbvie Inc.
- Amgen Inc.
- Bausch Health Companies Inc.
- Cara Therapeutics, Inc.
- Cipla Ltd.
- Eilly Lilly and Company
- Evelo Biosciences
- Galderma S.A.
- Leo Pharma
- Mc2 Therapeuitics
- Novan, Inc
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc
- Sanofi
- Trevi Therapeutics
- Viatris Inc. (Mylan Nv)
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 385 |
| Published | August 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 7849.4 million |
| Forecasted Market Value ( USD | $ 11186.15 million |
| Compound Annual Growth Rate | 3.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
